Avalon Pharmaceuticals, Inc. has announced the expiration of its agreement with sanofi-aventis. The agreement in December 2003 established a collaboration to utilize molecular cytogenetics to identify and validate oncology targets.
The agreement expired as a result of sanofi- aventis' decision not to advance targets that were a focus of the collaboration for further validation.
"We have appreciated the close collaboration with sanofi-aventis on this program," said Paul Young, Ph.D., Vice President of Research for Avalon.
"While they did not select any targets from this program, we expect to continue validation studies on several of the genes as potential Avalon drug discovery targets."